My recent paper with Mark Lupo,
Glenn Braunstein et al showed that cfDNA was unable to be of
use in the diagnosis or thyroid cancer in thyroid nodules. FNA and molecular markers direct6 from the nodules were not improved by circulation cfDNA measurements. There were no
differences in cfDNA from benign or cancer nodules.One KRAS G12V mutation from a stage IVA papillary carcinoma. 2/43 benign nodules patients had cfDNA detected.\
A larger panel with proteomics may be of value.
Full article at
Endocrine Practice 24(5) 2018 453-59